Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
ESG rating upgraded! Healthy Yuan Pharmaceutical Group interprets social responsibility with actions
Published Time：
2021-08-17
Recently, Morgan Stanley Capital International, hereinafter referred to as “MSCI” ）released the latest news on ESG ratings. This rating aims to measure a company's ability to withstand risks in terms of long-term development and financial capabilities. ESG Joincare Pharmaceutical Group Industry Co., Ltd.（ 600380.SH ）'s ESG (i.e., environmental, social, and governance) rating has been upgraded from BB to BBB ，achieving improvements in scores on issues such as environmental protection, human capital development, and universal health. Since 2018 year, it was first included in MSCI ESG rating, Health Yuan's sustainable development management has attracted much attention. This year's rating upgrade demonstrates the capital market's high recognition of the group and confidence in its future development.
MSCI is one of the world's most influential capital market rating agencies, MSCI indices have also become the most widely used investment targets by global portfolio managers. Its ESG rating results have become an important basis for decision-making by major global investment institutions, MSCI ESG equity and fixed income index products are increasingly favored by the global capital market. MSCI 's ESG rating mainly obtains information from public sources, collecting data from over 8,700 listed companies on 35 key issues ESG ，covering pollution and emissions, human capital, data security, business ethics, etc. Different industries select different key issues for scoring, and score each issue from the perspectives of risk exposure and risk management of listed companies.
Based on the relative results of global peers, MSCI ESG the rating is obtained by weighting the scores of each key issue and adjusting it by industry to obtain ESG rating letter grade: The rating level is divided into seven levels from “AAA” （highest）to “CCC” （lowest）.
In recent years, Health Yuan Pharmaceutical Group has attached great importance to ESG relevant content and continuously improved its social responsibility management structure. 2020 In the year, Health Yuan formally established the Board of Directors' Social Responsibility Committee to coordinate the management of the company's sustainable development strategy and planning, clarified the working mechanism of the social responsibility management working group, and formed standardized management through the formulation of the "Social Responsibility Management System", promoting the continuous improvement of social responsibility management level.
Health Yuan is an innovative R&D-oriented comprehensive pharmaceutical group covering multiple fields, including chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, health products, diagnostic reagents and equipment. It integrates R&D, production, sales, and services, with a complete industrial chain. It has long been deeply involved in the domestic inhalation preparation market, and many of its inhalation preparation products have been approved for marketing and successfully entered the national centralized procurement process. While promoting the development of its main business, Health Yuan has deeply practiced social responsibility, actively participated in social welfare undertakings, continuously promoted the development of the big health industry, paid attention to the accessibility, affordability, and rational use of medical products and services, actively responded to the national medical insurance catalog access and negotiation work, and is committed to providing patients with high-quality medicines at reasonable prices. At the same time, Health Yuan and its holding subsidiary, Lizhu Group, jointly launched a special chronic disease poverty alleviation public welfare project targeting chronic disease patients, donating chronic disease treatment drugs to elderly patients with hypertension, hyperlipidemia, and cardiovascular and cerebrovascular diseases in areas in need of assistance. Currently, the project has benefited thousands of chronic disease patient families.
In the future, Health Yuan will continue to consolidate ESG the work foundation of the following issues, improve management efficiency, comprehensively promote lean management, strive to improve the level of corporate governance, promote the high-quality and sustainable development of the company, and use practical actions to call on more partners to practice social responsibility together!
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.